Company news

Invion Ltd. news in 2026

Invion Ltd.'s news releases, calls and decks from 2026, newest first.

View company

Appendix 4C and Quarterly Activities Report - September 2026

October 28, 2026

Notice of Annual General Meeting/Proxy Form

October 23, 2026

Proposed issue of securities - IVX

October 20, 2026

Funding Agreements Cover Up to 85% of Clinical Trials Costs

October 20, 2026

Funding Agreements Cover Up to 85% of Clinical Trials Costs

October 20, 2026

Photosoft & Novel Immunotherapy Collab Partnership

October 19, 2026

PER: Percheron and Invion Explore Cancer Combination Therapy

October 19, 2026

Recruitment Conclusion for Ph 1 NMSC Trial & Advance to Ph 2

October 18, 2026

Application for quotation of securities - IVX

October 15, 2026

Proposed issue of securities - IVX

September 29, 2026

Director Loans

September 29, 2026

Appendix 4G and Corporate Governance Statement

August 26, 2026

Appendix 4E and Annual Report

August 26, 2026

Initial Director's Interest Notice - Paul FIeld

August 20, 2026

Final Director's Interest Notice - Alistair Bennallack

August 20, 2026

IVX Credentialed International Biotech Leader Joins Board

August 18, 2026

Appendix 4C and Quarterly Activities Report - June 2026

July 30, 2026

Photosoft Platform Expands to Eye Diseases Via Partnership

May 18, 2026

Appendix 4C and Quarterly Activities Report - March 2026

April 30, 2026

Skin Cancer Trial Moves to BCC With More Encouraging Signals

April 21, 2026

Appendix 4D and Half Year Financial Report

February 26, 2026

Appendix 4C and Quarterly Activities Report - December 2025

January 30, 2026

Major Shareholders Lead Invion $1.3M Capital Raise

January 30, 2026

Trading Halt

January 28, 2026

Pause in Trading

January 28, 2026

Decks in 2026